View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
August 23, 2021updated 01 Sep 2021 9:13am

Resumed trials continue to increase further

Since the beginning of the Covid-19 pandemic, the number of resumed trials has increased, with the US having the largest number.

Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of planned trials or withdrawn them completely and others have suspended enrollment in their ongoing trials or terminated the trials altogether. The majority of trial disruptions can be attributed to patient safety measures, strict lockdown requirements, social distancing procedures and the high demand on medical professionals to treat Covid-19 patients.

As the initial peak of the virus started declining, many trials were set to resume activity. However, the number of confirmed Covid-19 cases is increasing again due to the emergence of new variants.

The Covid-19 Dashboard on GlobalData’s Pharma Intelligence Center dynamically tracks both disrupted and resumed trials.

As of August 19, the number of resumed trials is currently at 1,086. Out of these trials, 52.7% are currently recruiting participants, 21.9% have completed recruitment but are still ongoing and 0.2% have yet to start recruiting subjects. The figure below shows that the number of trials resuming has increased slightly.

The US has the highest proportion of resumed trials at 69.3%, followed by the UK at 9.3%, Spain at 7.5%, France at 7.1% and Germany at 6.8%.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy